AARD
$5.33
Aardvark Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases.
Recent News
A Look At Aardvark Therapeutics (AARD) Valuation After The Voluntary Pause Of Its Phase 3 HERO Trial
Aardvark Therapeutics (AARD) has drawn investor attention after voluntarily pausing its Phase 3 HERO trial for ARD-101 in Prader-Willi Syndrome, following reversible cardiac observations at higher than target doses. See our latest analysis for Aardvark Therapeutics. The voluntary HERO trial pause and related analyst downgrades have coincided with sharp weakness in Aardvark Therapeutics’ share price, with a 7 day share price return of 54.44% and a year to date share price return of 57.24%,...
Aardvark Therapeutics (AARD) Is Down 61.4% After Pausing Phase 3 HERO Trial Over Cardiac Safety Questions
Aardvark Therapeutics recently paused its Phase 3 HERO trial of ARD-101 for Prader-Willi Syndrome after reversible cardiac-related observations emerged at above-target doses in a healthy volunteer study, delaying previously expected topline data timelines. The pause comes despite ARD-101 holding both Orphan Drug and Rare Pediatric Disease designations from the FDA for Prader-Willi Syndrome, underscoring the program’s regulatory importance and complexity. With the Phase 3 HERO trial on hold...
Why Aardvark Therapeutics Just Lost More Than Half Its Value
Biotech stock Aardvark Therapeutics crashed Monday after the company voluntarily stopped its Prader-Willi study.
Sector Update: Health Care Stocks Retreat Late Afternoon
Health care stocks declined late Monday afternoon with the NYSE Health Care Index falling 1.2% and t
Safety concerns spur Aardvark to halt key Prader-Willi drug trial
The detection of certain cardiac issues in a study of healthy volunteers led Aardvark to pause a Phase 3 trial only months before an expected data readout.